Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study)
Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-009A) and Precision Treatment Project of Surgical Oncology of Tianjin Medical University Cancer Institute and Hospital (No. ZLWKJZZL14).
Authors
- Zhao-Long Pan
- Wei‐Yang Lu (ORCID: https://orcid.org/0009-0006-2208-6660)
- Wei Zhang (ORCID: https://orcid.org/0000-0001-5292-7308)
- Bingyi Xiao
- Hong Zheng (ORCID: https://orcid.org/0000-0002-8884-8211)
- Wei Gao (ORCID: https://orcid.org/0000-0002-6054-382X)
- Zhao Xiao-hui
- Chen Liu (ORCID: https://orcid.org/0009-0003-0430-6146)
- Qiang Li (ORCID: https://orcid.org/0000-0002-4384-8226)
- Dongyang Li (ORCID: https://orcid.org/0000-0002-6317-7853)
- Lu Yang (ORCID: https://orcid.org/0000-0001-9566-6259)
- Xiaomeng Liu (ORCID: https://orcid.org/0000-0001-7420-715X)
- Junbo Cao
- Xu Bao (ORCID: https://orcid.org/0000-0003-3350-2456)
- Guangtao Li (ORCID: https://orcid.org/0000-0003-4719-1564)
- Weihao Zhang (ORCID: https://orcid.org/0000-0002-9301-8538)
- Wenge Xing (ORCID: https://orcid.org/0000-0003-3882-2934)
- Xiaolin Zhu
- Tian-Qiang Song (ORCID: https://orcid.org/0000-0002-8710-6339)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103217
- Citations
- 6
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 7.93
Funders
- Tianjin Medical University
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences